Rhesive inborn errors of type I IFN immunity in children with COVID-19 pneumonia

Qian Zhang1,2,3*, Daniela Matouzzo1,2,3, Jérémie Le Pen4,5*, Danyel Lee1,2,6, Leen Moens4,6, Takaki Asano7, Jonathan Bohlen2,3,7, Zhiyong Liu8,9, Marcela Moncada-Velez10, Yasemin Kendir-Demirkol11, Huie Jing12, Lucy Bizien13,14, Astrid Marchal15,16, Hassan Abbahassani17,18, Selket Delafontaine19,20, Giorgia Bucchi21, COVID Human Genetic Effort, Gulsum Ical Bayhan22,23,24, Sevki Keles25,26, Ayka Kiyikm27,28, Selda Hancerli29, Filomeen Haeyrnick30, Benoît Florkin31, Nevin Hatipoglu32, Tayfun Ozcelik33, Guillaume Morelle34, Mayana Zatz35,36, Lisa F.P. Ng37,38, David Chien Lye39,40,41, Barnaby Edward Young39,40,41, Yee-Sin Leo42,43,44, Clifton L. Dalgar45,46, Richard P. Liftin47,48,9,10,11, Laurent Rena49,50,51,52,53, Isabelle Meys54,55, Emmanuel Jouanguy56,57,58,59,60,61, Lennart Hammarström62,63,64,65,66,67,68,69,70,71, Qiang Pan-Hammarström72,73,74, Bertrand Boisson1,2,3,75, Paul Bastard1,2,3,76, Helen C. Su77, Stéphanie Boisson-Dupuis78,79,80,81, Lauren Abel1,2,82,83,84, Charles M. Rice85,86, Shen-Yang Zhang87,88,89,90,91, Auriéle Cobat1,2,92,93,94,95, and Jean-Laurent Casanova96,97,98,99,100,101,102,103,104,105,106,107,108

Rhesive inborn errors of type I interferon (IFN) immunity can underlie critical COVID-19 pneumonia in unvaccinated adults. The risk of COVID-19 pneumonia in unvaccinated children, which is much lower than in unvaccinated adults, remains unexplained. In an international cohort of 112 children (<16 yr old) hospitalized for COVID-19 pneumonia, we report 12 children (10.7%) aged 1.5–13 yr with critical (7 children), severe (3), and moderate (2) pneumonia and 4 of the 15 known clinically recessive and biochemically complete inborn errors of type I IFN immunity: X-linked recessive TLR7 deficiency (7 children) and autosomal recessive IFNAR1 (1), STAT2 (1), or TYK2 (3) deficiencies. Fibroblasts deficient for IFNAR1, STAT2, or TYK2 are highly vulnerable to SARS-CoV-2. These 15 deficiencies were not found in 1,224 children and adults with benign SARS-CoV-2 infection without pneumonia (P = 1.2 × 10−13) and with overlapping age, sex, consanguinity, and ethnicity characteristics. Recessive complete deficiencies of type I IFN immunity may underlie ~10% of hospitalizations for COVID-19 pneumonia in children.
Introduction

SARS-CoV-2 infection in unvaccinated individuals is silent or mild (i.e., causing a benign upper respiratory tract disease) in ~80% of cases (Brodin, 2021; Telenti et al., 2021; Zhang et al., 2022). Moderate, nonhypoxemic pneumonia is seen in ~10% of cases. Hypoxemic pneumonia occurs in ~10% of cases and can be severe (~7%, with O2 < 6 liters/min) or critical (~3%, with O2 < 6 liters/min and/or mechanical ventilation). The overall infection fatality rate (IFR) is ~1%, with significant geographic variations. The risk of death doubles every 5 yr of age, from childhood onward, accounting for >99.9% of patients with critical pneumonia being adults (over 16 yr of age; O’Driscoll et al., 2021). We tested patients for influenza susceptibility genes, and we identified autosomal inborn errors of TLR3-dependent and -independent type I IFN immunity in ~3% of adults with critical COVID-19 pneumonia, including, surprisingly, autosomal recessive (AR) deficiencies of IFNAR1 or IRF7 in four previously healthy, unrelated adults aged 25–50 yr (Zhang et al., 2020b). AR IRF7 deficiency impairs the production of type I and III IFNs, especially in plasmacytoid dendritic cells (pDCs), which normally constitutively express high levels of IFR7 (Ciancanelli et al., 2015), whereas AR IFNAR1 deficiency impairs cellular responses to type I but not III IFNs, across cell types (Hernandez et al., 2018). Two patients with AR IFNAR1 deficiency, one aged 3 yr and the other aged 13 yr (Abolhassani et al., 2022; Khammohammedi et al., 2021), and a 3.5-yr-old child with AR TBK1 deficiency (Schmidt et al., 2021) were subsequently reported.

Using an unbiased genetic approach, we also identified X-linked recessive (XR) TLR7 deficiency in 17 male patients aged 7–71 yr with critical COVID-19 pneumonia, accounting for ~1% of cases in men (Asano et al., 2021). These patients included the only known patient with ataxia-telangiectasia who developed critical disease (Abolhassani et al., 2021). Moreover, 9 (aged 21–57 yr) of the other 19 patients with a proposed diagnosis of TLR7 deficiency (Fallerini et al., 2021; Mantovani et al., 2021; Pessoa et al., 2021; Solanich et al., 2021; van der Made et al., 2020) actually had TLR7 deficiency according to the results of our own biochemical study (Asano et al., 2021). Finally, we found preexisting autoantibodies (auto-Abs) neutralizing type I IFNs in ~15% of critical cases, with a higher proportion in patients older than 70 yr (Bastard et al., 2021a; Bastard et al., 2020).

Human type I IFNs are, therefore, essential for protective immunity to SARS-CoV-2 in the respiratory tract (Casanova and Abel, 2021; Zhang et al., 2022). These findings also incriminated two key cell types governing type I IFN immunity to the virus: respiratory epithelial cells (RECs), which express TLR3 and allow viral replication (Zhang et al., 2022; Zhang et al., 2020b), and pDCs, which express TLR7 and can sense the virus but do not allow viral replication (Asano et al., 2021; Zhang et al., 2022). TLR3 is an endosomal sensor of double-stranded RNA (dsRNA) that governs tonic type I IFN levels in several nonhematopoietic cell types, including RECs (Alexopoulou et al., 2001; Gao et al., 2021), whereas TLR7 is an endosomal sensor of single-stranded RNA (ssRNA; Diebold et al., 2004; Heil et al., 2004; Lund et al., 2004).

The penetrance of AR IFNAR1 and IRF7 deficiencies for critical COVID-19 appears to be complete, whereas that of XR TLR7 deficiency is high, but incomplete, especially in young patients (Asano et al., 2021). Consistently, critical COVID-19 pneumonia is both much less common and much less well understood in children than in adults. There are 15 known inborn errors of type I IFN that are recessively inherited and biochemically complete (Meyts and Casanova, 2021): mutations of TLR3 (Guo et al., 2011; Zhang et al., 2007), TICAM1 (Sancho-Shimizu et al., 2011), UNC93B1 (Casrouge et al., 2006), TLR7 (Asano et al., 2021), IRAK4 (Nishimura et al., 2021; Picard et al., 2003), MYD88 (Giardino et al., 2016; von Bernuth et al., 2008), IFIH1 (Asgari et al., 2017; Chen et al., 2021; Lamborn et al., 2017), TBK1 (Schmidt et al., 2021; Taft et al., 2021), IRF7 (Ciancanelli et al., 2015; Zhang et al., 2020b), IFNAR1 (Abolhassani et al., 2022; Bastard et al., 2021c; Hernandez et al., 2019), IFNAR2 (Bastard et al., 2021d; Duncan et al., 2015), TYK2 (Minegishi et al., 2006; Sarrafzadeh et al., 2020), STAT1 (Dupuis et al., 2003; Le Voyer et al., 2021), STAT2 (Freij et al., 2020; Hambleton et al., 2013), and IRF9 (Bravo García-Morato et al., 2019; Hernandez et al., 2018). Deficiencies of TLR3 and TRIF (encoded by TICAM1) disrupt the TLR3 pathway, whereas deficiencies of TLR7, MYD88, and IRAK4 affect the TLR7 pathway. UNC93B1 deficiency impairs both TLR3 and TLR7 responses. TBK1 deficiency impairs responses to TLR3, TLR7, and IFHI1. Deficiencies of MYD88, IRAK4, UNC93B, and TBK1 also disrupt the TLR8- and TLR9-dependent induction of type I IFNs. Finally, deficiencies of IFNAR1, IFNAR2, TYK2, STAT1, STAT2, and IRF9 impair cellular responses to type I IFN (Casanova and Abel, 2021; Zhang et al., 2022).

These disorders (or, by inference from their milder, dominant form, for autosomal disorders, underlined) are associated with severe viral diseases, including influenza pneumonia (TLR3, IRF7, IFN9, STAT1, STAT2; Alouani et al., 2019; Ciancanelli et al., 2015; Hernandez et al., 2018; Le Voyer et al., 2021), COVID-19 pneumonia (TLR3, UNC93B1, TBK1, TRIF, IRF3, IRF7, IFN7, IFNAR2, IFNAR1, TLR7; Abolhassani et al., 2022; Asano et al., 2021; Schmidt et al., 2021; Solanich et al., 2021; van der Made et al., 2020; Zhang et al., 2020b), rhinovirus or respiratory syncytial virus pneumonia (MDA5, encoded by IFIH1; Asgari et al., 2017; Lamborn et al., 2017), herpes simplex virus encephalitis (IFNAR1, STAT1, TLR3, TRIF, TYK2, UNC93B1; Bastard et al., 2021c; Casrouge et al., 2006; Dupuis et al., 2003; Guo et al., 2011; Kreins et al., 2015; Minegishi et al., 2006; Sancho-Shimizu et al., 2011), adverse reactions to measles, mumps, and rubella (MMR) or yellow fever virus (YFV) vaccines (IFNAR1, IFNAR2, STAT1, STAT2; Bastard et al., 2022; Burns et al., 2016; Duncan et al., 2015; Duncan et al., 2022; Hambleton et al., 2013; Hernandez et al., 2019; Moens et al., 2017), enterovirus encephalitis (TLR3, MDA5; Chen et al., 2021), EBV viremia (MYD88; Chiriac et al., 2019), and human herpesvirus-6 (HHV6) infection (IRAK4; Nishimura et al., 2021). Over the last two decades, 105 children with these disorders have been reported, and many more were probably diagnosed. We tested the hypothesis that these 15 recessive disorders could underlie
COVID-19 pneumonia in at least some patients <16 yr of age with no history of inborn errors of immunity (IEIs) enrolled by the COVID Human Genetic Effort (http://www.covidhge.com). We did not enroll patients known to suffer from any of these recessive disorders before having COVID-19 in this study, to prevent bias.

Results and discussion
Identification of type I IFN–related candidate genes in children hospitalized for COVID-19 pneumonia
We studied 112 children hospitalized for COVID-19 pneumonia, including 25 with moderate, 15 with severe, and 72 with critical pneumonia. The inclusion criteria were (1) patient under the age of 16 yr; (2) SARS-CoV-2 PCR–positive respiratory tract sample; and (3) radiological proof of COVID-19 pneumonia (Fig. 1A). Patients already known to have inborn errors of type I IFN immunity were not enrolled in our international cohort. At the time of hospitalization, the patients were living in 14 countries: Belgium (n = 2); Brazil (5); Czech Republic (2); Egypt (2); France (10); Hong Kong, China (1); Iran (17); Italy (9); Peru (1); Spain (16); Switzerland (1); Turkey (33); United Arab Emirates (1); and United States (12). Of the 112 patients included in this study, 47 had been reported before (Asano et al., 2021; Bastard et al., 2021a; Bastard et al., 2020; Zhang et al., 2020b): 39 critical cases, 7 severe cases, and 1 moderate case. The candidate genes encoded the type I IFN–inducing dsRNA sensors endosomal TLR3 and cytosolic MDA5 (IFIHI), the ssRNA endosomal sensor TLR7; key components of these and other IFN–inducing pathways, including UNC93B1 (for the TLR3 and TLR7 pathways), TRIF (TICAM); for the TLR3 pathway), MYD88 and IRAK4 (for the TLR7 pathway; Onodi et al., 2021); and TBK1 (for TLR3, TLR7, MDA5, and other pathways); the type I IFN receptor chains IFNAR1 and IFNAR2; and key components of their signaling pathway, including TYK2, STAT1, STAT2, IRF7, and IRF9 (Casanova and Abel, 2021; Duncan and Hambleton, 2021; Meys and Casanova, 2021; Zhang et al., 2020a). TLR7 is the only X-linked gene, the other 14 genes being autosomal. These are the only known loci in humans for which inborn errors have been reported that (a) are recessive, as opposed to dominant, (b) are biochemically complete (as opposed to partial deficiencies), and (c) impair type I IFN immunity. All reported causal variants at 13 of these 15 loci have a global Genome Aggregation Database (GnomAD, v2.1) minor allele frequency (MAF) <10⁻³ (IFIHI and TLR3 being the exceptions, with causal variants having MAFs of ≤6.7 × 10⁻³ and 1.7 × 10⁻³, respectively). The penetrance of most these genotypes for most associated viral diseases is incomplete. We thus tested the hypothesis that these 15 recessive inborn errors of type I IFN immunity may underlie moderate, severe, or critical COVID-19 in at least some children, who may not necessarily have suffered from other unusually severe viral illnesses before COVID-19.

Enrichment in rare homozygous or hemizygous variants at the 15 candidate loci
We collected whole-exome sequencing (WES)/whole-genome sequencing (WGS) data for the 112 children hospitalized for COVID-19 pneumonia (hereafter referred to simply as “patients”; 90 WES and 22 WGS) and for 1,224 children and adults with asymptomatic or mild SARS-CoV2 infection (including 82 children aged 6 mo to 16 yr, 90 young adults aged 17–25 yr, and the remaining 1,052 adults >25 yr old, hereafter referred to as “controls”; 714 WES and 510 WGS). The mean age (SD) of the patients was 9.4 (4.6) yr, with a male-to-female ratio of 2.3 (78 boys and 34 girls). By contrast, the controls had a mean age (SD) of 44.8 (19.3) yr (range: 6 mo to 105 yr) with a male-to-female ratio of 0.66 (306 male and 918 female). The patients were of Middle Eastern (n = 52), European (n = 29), American admixed (n = 12), sub-Saharan African (n = 10), North African (n = 4), South Asian (n = 4), and East Asian (n = 1) origin, based on principal component analysis (PCA) of their exomes (Fig. 1B; Belkadi et al., 2016). Among the 112 patients, 26 (23.2%) were considered to have been born to consanguineous parents based on exome homozygosity rates >1% (Belkadi et al., 2016). This rate of consanguinity is higher than the global level of 8.5% (Modell and Darr, 2002). The control individuals were of Middle Eastern (n = 153), European (n = 895), American admixed (n = 77), sub-Saharan African (n = 34), North African (n = 17), South Asian (n = 28), and East Asian (n = 20) origin, based on PCA (Fig. 1B). Among these 1,224 individuals, 75 (6.1%) were considered to have been born to consanguineous parents, based on homozygosity rates >1%. The proportion of patients born to consanguineous parents was significantly higher than that in controls (Fisher’s exact test, P = 3.5 × 10⁻⁶), but, in terms of absolute numbers, there were more controls (75) than cases (26) born to consanguineous parents. We analyzed the WES or WGS data for these individuals, including for all 15 recessive inborn errors of type I IFN immunity. We then selected homozygous and potential compound heterozygous nonsynonymous and essential splice site variants at the 14 autosomal loci, and hemizygous variants at the TLR7 locus. We searched for very rare (MAF <10⁻³) variants among the GnomAD nonsynonymous or splice-site variants with a combined annotation-dependent depletion score greater than the gene-specific mutation significance cutoff, for the 15 genes (Itan et al., 2016). We also searched for rare homozygous or hemizygous copy number variants for the same genes (Bigjo et al., 2021; Chen et al., 2016). A burden test adjusted for sex and the first five principal components for the 15 loci revealed highly significant enrichment in rare homozygous, potential compound heterozygous, or hemizygous variants in patients relative to controls (P = 1 × 10⁻⁷; odds ratio = 26.6; 95% confidence interval = 7.3–96.6), with 12 carriers among the patients (10.7%, including four homozygotes, one potential compound heterozygote, and seven hemizygotes) vs. three (0.25%, two homozygotes, one hemizygote) among the controls. The three carriers among the controls were 44, 50, and 53 yr old. Restricting the analysis to predicted loss-of-function variants (pLOF) also revealed significant enrichment in such variants, with four carriers among the patients (3.5%) and none among the controls (P = 1.4 × 10⁻⁴). A similar result was obtained when the analysis was performed on pLOF variants without restriction on the basis of MAF. TLR7 deficiency has already been reported to underlie critical COVID-19 in adults (Asano et al., 2021). We therefore also analyzed enrichment, focusing on the 14 autosomal genes, and found a significant enrichment in rare pLOF (1.4 × 10⁻⁴) or rare pLOF and missense variants (P = 9.6 × 10⁻⁴).
Figure 1. Recessive inborn errors of the type I IFN pathway underlie life-threatening viral infections. (A) Chest computed tomography scan on day 6 after disease onset in P1, showing ground-glass opacification and consolidation in both lungs. (B) PCA analysis of patients and controls. KGP, 1000 Genomes Project database. (C) Pedigrees and familial segregation of the variants identified. Black symbols, patients with moderate to critical COVID-19 pneumonia; symbols with vertical bars, individuals with asymptomatic SARS-CoV-2 infection; blue + and − symbols, seropositive and seronegative for SARS-CoV-2, respectively.
Finally, the enrichment analyses performed on homozygous synonymous variants or on heterozygous nonsynonymous and essential splice variants with MAF <10⁻⁴ for the 15 loci were not significant (P = 0.05 and 0.79, respectively), indicating that our ethnicity-adjusted burden test was well calibrated.

Candidate genotypes detected by exome and genome sequence analyses

Our analysis led to the identification of 12 unrelated children with COVID-19 pneumonia, each of whom carries a biallelic or hemizygous variant of one of the 15 candidate genes (Table 1 and Fig. 1 C), as confirmed by Sanger sequencing. One of the patients had two compound heterozygous variants of STAT2 (S613F and Q685X; the compound heterozygosity of the two mutations was confirmed by family segregation analysis), and three unrelated patients had the same homozygous missense variant of TYK2 (P216Fs*14; AR inheritance was confirmed for all three patients by family segregation analysis). Seven patients had hemizygous missense variants of TLR7 (one newly identified patient with I174R and six previously described patients with N75H, D244Y, L372M, and H781L; Abolhassani et al., 2021; Asano et al., 2021), and one patient had a large homozygous genomic deletion in IFNAR1 (H263fs*14, 4,394-bp deletion encompassing exons 7–8 of the IFNAR1 gene; chr2: 34,719,302–34,723,696, GRCh37–hg19; Abolhassani et al., 2022). The 12 patients originated from 10 kindreds and four countries (Belgium, Russia, Iran, and Turkey; Table 1). Eight of the 12 patients were tested for auto-Abs against type I IFNs, and all were negative (Bastard et al., 2021a; Bastard et al., 2020). We also identified one control with a hemizygous missense variant of TLR7 (H782D), another with a homozygous missense variant of IFIHI (Q415K), and a third with a homozygous missense variant of IRF7 (L128M). These three controls originated from three different countries: Brazil, France, and Singapore (Table 1). We also screened our sick children for very rare (MAF <10⁻⁴ according to gnomAD database) homozygous pLOF variants of the 337 genes known to underlie AR or XR IEIs (Tangye et al., 2020; Tangye et al., 2021). We did not identify additional candidate recessive defects. We further screened the full list of 452 IEI genes (including those underlying only dominant disorders) for very rare (MAF <10⁻⁴) pLOF variants. There was no significant global or gene-specific enrichment in cases vs. controls in tests of a dominant model.

Autosomal and XR type I IFN deficiencies in 12 children

Three of the five patients not previously reported, P2, P3, and P4, carried the same TYK2 variant (P216Fs*14), which had already been shown experimentally to be loss-of-expression in cells from patients (Fuchs et al., 2016). We confirmed that this variant was LOF (not depicted). By contrast, the two STAT2 variants carried by P1 and the TLR7 variant carried by P5 have yet to be studied. We first tested the STAT2 variants. Following transient overexpression in HEK293T cells, S613F was detected at a molecular weight (MW) similar to that of WT STAT2 (113 kD), whereas Q685X had a lower MW of ~80 kD; both these variants resulted in the production of only small amounts of protein (Fig. 2 A). Moreover, in HEK293T cells expressing the S613F or Q685X variant, IFN-α2a stimulation did not induce the phosphorylation of STAT2 (pSTAT2), as in cells expressing the known LOF STAT2 variant R510X, but not those expressing WT STAT2 (Fig. 2 A). We then transiently transfected the STAT2-deficient fibrosarcoma cell line U6A with STAT2 variants to investigate their transcriptional activity. Upon IFN-α2a stimulation, cells transfected with WT STAT2 displayed an induction of transcription for three classical IFN-stimulated genes (ISGs; IFIT1, IFIT2, and RSAD2), whereas cells transfected with the patient’s variants and the LOF variant R510X did not (Fig. 2 B). Thus, biochemical tests of the two STAT2 variants from P1 indicated that both were LOF. We tested simian virus 40–transformed fibroblasts (SV40 fibroblasts) from P1. The phosphorylation of STAT2 (pSTAT2), but not that of STAT1, in response to stimulation with IFN-α2b was abolished, whereas the response to IFN-γ remained intact (Fig. 2 C). Finally, we assessed the expression and function of P5’s TLR7 variant following transient overexpression in HEK293T cells. The I174R variant of TLR7 failed to activate the NF-κB luciferase reporter when cells were stimulated with the TLR7 agonist R848, as observed for the known LOF TLR7 variant F670fs (Fig. 2 D), although the mutant protein was produced in normal amounts at the expected MW (Fig. 2 E). We can, therefore, conclude that P5’s TLR7 variant is LOF. These data suggest that P1 has AR STAT2 deficiency and that P5 has XR TLR7 deficiency. The first five patients (P1–P5) reported here, thus, had recessive complete inborn errors of type I IFN immunity. Our findings implicate AR STAT2 and TYK2 deficiencies as new genetic etiologies of COVID-19 pneumonia. Together with the seven previously reported TLR7-deficient (P6–P11) and IFNAR1-deficient (P12) children with COVID-19 pneumonia (Abolhassani et al., 2021; Asano et al., 2021), these five patients bring us to a total of 12 patients (10.7%) in our pediatric COVID-19 cohort with recessive complete inborn errors of type I IFN immunity, including 9.0% of boys for XR traits and 4.5% of children with AR traits. As a means of obtaining a better estimate of this latter proportion, we screened for pairs of individuals with first- to third-degree relationships (kinship ≥0.0442), using the appropriate option of King software (Manichaikul et al., 2010) to estimate the pairwise relatedness between patients. We found two additional pairs of distant relatives in the patient cohort (besides P6/7 and P8/9), and 33 in the control cohort. After the exclusion of one sample per pair, we estimated the frequency of AR type I IFN IEI in our pediatric cohort at 9.3% (10 of 108 unrelated patients).

Demographic and clinical features of the 12 patients

Five of the 12 patients (P1–P5) are newly described children aged 1.5–13 yr, living in Turkey (P1–P4) and Belgium (P5). All five developed COVID-19 pneumonia of various degrees of severity, from moderate to critical (Table 1), and three had histories of other severe viral diseases before COVID-19 pneumonia, which had not been explored genetically and immunologically. The other seven patients (P6–P12) are previously described children aged 3–13 yr, living in Turkey (P6–P9), France (P10), and Iran (P11 and P12; Abolhassani et al., 2022; Abolhassani et al., 2021; Asano et al., 2021). All seven developed COVID-19 pneumonia of various degrees of severity, from moderate to critical. P11 and P12 had histories of bacterial and fungal infections (Table 1).
Table 1. Genetic, immunological, and clinical description of pediatric patients with recessive inborn errors of type I IFN immunity and COVID-19 pneumonia

| Patient | Gene | Gender | Age (yr) | Ethnicity/residence | COVID-19 pneumonia severity | Systemic inflammation | Other viral infections | Other infections and clinical history | Outcome | Publication |
|---------|------|--------|----------|---------------------|-----------------------------|------------------------|----------------------|-----------------------------------|---------|-------------|
| P1      | STAT2 S613F/Q685X (LOF/LOF) | M | 12 | Middle East/Turkey | Critical | Yes | Aseptic meningitis and Kawasaki disease after MMR vaccination at the age of 1 yr; recurrent severe influenza pneumonia requiring hospitalization since the age of 2 yr | | Survived | This report |
| P2      | TYK2 P216fs/P216fs (LOF) | F | 2 | Middle East/Turkey | Moderate | | Hospitalized for infection of VZV vaccine at the age of 2 yr | Hospitalized for sepsis during the neonatal period; Admitted to ICU twice for fever and dyspnea before 5 mo old, diagnosed with Kawasaki disease at the age of 11 mo | Survived | This report |
| P3      | TYK2 P216fs/P216fs (LOF) | M | 4 | Middle East/Turkey | Critical | | Admitted to ICU for influenza pneumonia at 3 yr; no adverse reaction to MMR vaccination | Hospitalized for sepsis during the neonatal period | Survived | This report |
| P4      | TYK2 P216fs/P216fs (LOF) | M | 9 | Middle East/Turkey | Critical | | No adverse reaction to MMR vaccination | Recurrent bronchitis requiring hospital admission and inhaler therapy | Survived | This report |
| P5      | TLR7 N174R/Y (LOF) | M | 12 | Europe/Belgium | Severe | | No adverse reaction to MMR vaccination | | Survived | This report |
| P6      | TLR7 N75H/Y (LOF) | M | 7 | Middle East/Turkey | Severe | | No adverse reaction to MMR vaccination | | Survived | Asano et al. (2021) |
| P7      | TLR7 N75H/Y (LOF) | M | 12 | Middle East/Turkey | Severe | | No adverse reaction to MMR vaccination | | Survived | Asano et al. (2021) |
| P8      | TLR7 D244Y/Y (LOF) | M | 13 | Middle East/Turkey | Critical | | No adverse reaction to MMR vaccination | | Survived | Asano et al. (2021) |
| P9      | TLR7 D244Y/Y (LOF) | M | 5 | Middle East/Turkey | Moderate | | No adverse reaction to MMR vaccination | | Survived | Asano et al. (2021) |
| P10     | TLR7 H781L/Y (LOF) | M | 13 | Middle East/France | Critical | | No adverse reaction to MMR vaccination | | Survived | Asano et al. (2021) |

Zhang et al. Journal of Experimental Medicine 6 of 19

Type I IFN defect in children with COVID pneumonia

https://doi.org/10.1084/jem.20220131
| Patient | Gene | Gender | Age (yr) | Ethnicity/residence | COVID-19 pneumonia severity | Systemic inflammation | Other viral infections | Other infections and clinical history | Outcome | Publication |
|---------|------|--------|----------|--------------------|-----------------------------|-----------------------|----------------------|--------------------------------------|---------|-------------|
| P11     | TLR7 | M      | 7        | Middle East/Iran   | Critical                    |                       | No adverse reaction to MMR vaccination | Recurrent fever, upper respiratory tract infections and otitis media, pneumonia, since the age of 1 yr; diagnosed with failure to thrive, splenomegaly, anemia, and thrombocytopenia, osteomyelitis of the hip, since the age of 4 yr; diagnosed with hyper IgM syndrome since the age of 5 yr; and received IVIG since then | Survived | Asano et al. (2021); Abolhassani et al. (2021) |
| P12     | IFNAR1 | F      | 3        | Middle East/Iran   | Critical                    | Yes                   | No adverse reaction to MMR vaccination | Chronic severe chronic sinusitis and oral thrush since the age of 8 mo; severe mucormycosis of the nose and paranasal sinuses since the age of 2 yr | Deceased | Abolhassani et al. (2022) |
| C1      | TLR7 | M      | 53       | Europe/Brazil      | Asymptomatic                |                       |                      |                                     |         |             |
| C2      | IFIH1 | F      | 50       | North Africa/France | Asymptomatic                |                       |                      |                                     |         |             |
| C3      | IRF7 | M      | 44       | Southeast Asia/Singapore | Asymptomatic                |                       |                      |                                     |         |             |

M, male; F, female.

*Patient also carries a homozygous deleterious ATM mutation (Y2371X).
Figure 2. Novel deleterious variants of STAT2 and TLR7 underlie life-threatening COVID-19 in children. (A) STAT2 protein levels in HEK293T cells, with and without transfection with WT or mutant STAT2 plasmids, as assessed by Western blotting. The known LOF variant R510X served as an LOF control. (B) ISG induction upon stimulation with IFN-α2b, in STAT2-deficient U2A fibrosarcoma cells with and without transfection with the WT or STAT2 variants. qPCR results were normalized against WT. The known LOF variant R510X served as an LOF control. Experiments were repeated twice. (C) Phosphorylated STAT1 (p-STAT1) and p-STAT2 levels following stimulation with IFN-α2a or IFN-γ, as assessed by Western blotting, in SV40 fibroblasts from PI and previously published patients with AR complete IFNAR1, STAT1, or STAT2 deficiencies and cells from two healthy controls (C1 and C2). (D) HEK293T cells were transfected with TLR7 variants, the firefly luciferase gene regulated by NF-κB, and the constitutively expressed Renilla luciferase gene, and were then stimulated with the TLR7 agonist R848. Firefly luciferase activity levels were first normalized against Renilla luciferase activity, and then against WT activity. The known LOF variant F670fs served as an LOF control. Experiments were repeated four times. Error bars indicate the SD of repeats. (E) HEK293T cells were transfected with TLR7 variants, and protein levels were assessed by Western blotting.
P1 was a 12-yr-old Turkish boy, born to healthy non-consanguineous parents. He is compound heterozygous for STAT2 LOF mutations. He was admitted to the hospital for severe COVID-19 pneumonia (Fig. 1 A) followed by cold agglutinin-mediated autoimmune hemolytic anemia and other mucocutaneous presentations, leading to an initial diagnosis of multisystem inflammatory syndrome in children. P2 (female), P3 (male), and P4 (male) were unrelated 2-, 4-, and 9-yr-old children, each born to a different set of consanguineous Turkish parents. All three are homozygous for the same TYK2 LOF mutation. P2 was hospitalized for moderate COVID-19 pneumonia but did not require oxygen therapy. P3 and P4 were both admitted to the intensive care unit (ICU) for critical COVID-19 pneumonia requiring high-flow oxygen therapy. P5 is a 12-yr-old European boy living in Belgium who presented with severe pneumonia. He is hemizygous for a TLR7 LOF mutation (Table 1). The six previously reported TLR7-deficient children (P6–P11) were aged 5–13 yr and were living in Turkey, France, and Iran. They had moderate (one child), severe (two children), or critical (three children) COVID-19 pneumonia, and all survived (Table 1 and Fig. 1 B; Abolhassani et al., 2021; Asano et al., 2021). Finally, the previously reported IFNAR1-deficient child (P12) was a 3-yr-old girl who died from critical COVID-19 (Abolhassani et al., 2022). Moderate to critical COVID-19 pneumonia was a clinical presentation common to the 12 patients. All 11 patients tested mounted normal anti-S antibody responses after infection (Fig. 1 C). These findings suggest that biallelic or hemizygous LOF variants of IFNAR1, STAT2, TLR7, or TYK2 underlay the COVID-19 pneumonia in these children.

Penetrance of these recessive defects
We performed Sanger sequencing on family members for whom samples were available. We identified three individuals carrying the same genotype as the index patients (Fig. 1 B). The first, P5’s 52-yr-old maternal uncle, is hemizygous for the same TLR7 mutation and suffered from critical COVID-19 pneumonia requiring ICU admission and intubation. By contrast, both of P5’s parents had mild COVID-19 that did not require hospitalization (Fig. 1 B). The second was the 8-yr-old younger sibling of P10, who carried the same TLR7 genotype and had asymptomatic SARS-CoV-2 infection. The third was the 3-yr-old younger sister of P3, who carries the same genotype. She had a history of critical influenza pneumonia that required intubation and ventilation, as well as disseminated varicella. However, she was not infected with SARS-CoV-2 and she has remained seronegative to date (Fig. 1 C). The other sequences were consistent with a recessive trait, with relatives of index cases not hemizygous or homozygous for the pathogenic variant at any of the other three loci. Penetrance for COVID-19 pneumonia was, therefore, complete in the families with AR STAT2, TYK2, and IFNAR1 deficiencies reported here, but incomplete in at least one family with XR TLR7 deficiency, consistent with a previous report (Asano et al., 2021). The benign infection observed in the young TLR7-deficient relative of P10, and the critical diseases observed in P5’s uncle are consistent with our previous findings and suggest that tonic levels of type I IFN in the blood and tissues, which decrease with age (Bartleson et al., 2021; Loske et al., 2021; Pierce et al., 2020; Pierce et al., 2021; Schultze and Aschenbrenner, 2021; Shaw et al., 2013; Splunter et al., 2019; Stark and Darnell, 2012; Zhang et al., 2022), can modify the clinical impact of TLR7 deficiency. The development of COVID-19 pneumonia in a child with STAT2 deficiency is not surprising, given previous reports of critical pneumonia in patients with IFNAR1 or IRF7 deficiency (Zhang et al., 2020b). These defects probably display high, if not complete, penetrance for critical COVID-19. The occurrence of critical pneumonia in three unrelated patients with TYK2 deficiency is more surprising. Indeed, TYK2 deficiency impairs, but does not abolish, cellular responses to type I IFNs (Boisson-Dupuis et al., 2018). More TYK2-deficient patients infected with SARS-CoV-2 need to be diagnosed to estimate the corresponding penetrance.

Biallelic variants at the same loci in subjects with asymptomatic or mild infection
We investigated the hemizygous TLR7 variant (H782D), and the homozygous IFIH1 (Q415K) and IRF7 (L128M) variants, which were found in three infected adult controls. We assessed the production and activity of the proteins encoded by the three gene variants following transient overexpression in HEK293T cells. The H782D TLR7 protein had the expected MW and was produced in normal amounts. It also activated the NF-κB luciferase reporter, like WT TLR7, following stimulation with the TLR7 agonist R848 (Fig. 2, D and E). The Q415K MDAS protein had the expected MW and was produced in normal amounts. It also activated the IFN-β luciferase reporter, like WT MDAS, following intracellular poly(I:C) stimulation (Fig. 3, A and B). Finally, the L128M IRF7 protein was produced at the expected MW and in normal amounts. It activated the IFN-β luciferase reporter normally, with or without Sendai virus stimulation (Fig. 3, C and D). Consequently, the enrichment analysis restricted to biochemically deleterious genotypes was even more significant for the 15 loci (P = 1.9 × 10−11), for the 14 autosomal loci without TLR7 (P = 2.1 × 10−5), and remained significant after exclusion of the four pairs of related patients (P = 5.8 × 10−7). We found that 12 of 112 children with COVID-19 pneumonia had an AR or XR complete deficiency due to one of four of the 15 known recessive inborn errors of type I IFN immunity. None of the 15 recessive defects were found in 1,224 patients infected with SARS-CoV-2 who did not develop pneumonia. This significant enrichment, together with the known viral infection phenotypes of these four inborn errors (Abolhassani et al., 2022; Abolhassani et al., 2021; Bastard et al., 2021c; Duncan et al., 2015; Freij et al., 2020; Gothe et al., 2020; Hambleton et al., 2013; Hernandez et al., 2019; Kilic et al., 2012; Kreins et al., 2015; Minegishi et al., 2006; Moens et al., 2017; Nemoto et al., 2018; Sarrazadad et al., 2020) and the essential role of type I IFNs in protective immunity to SARS-CoV-2 (Asano et al., 2021; Bastard et al., 2021a; Bastard et al., 2020; Zhang et al., 2020b) suggest that these 12 children had COVID-19 pneumonia because of these recessive deficiencies of type I IFN immunity.

Estimated cumulative frequency of recessive deficiencies in the general population
We finally estimated the cumulative frequency of pLOF variants or pLOF homozygosity at the 15 loci using GnomAD (v2.1). We
found a cumulative frequency of pLOF variants of 0.031 and a cumulative frequency of pLOF homozygosity (including hemizygosity for TLR7) of $2 \times 10^{-4}$. When the analysis was restricted to the four genes with identified patients (IFNAR1, STAT2, TLR7, and TYK2), the cumulative frequency of recessive deficiency, based on the conservative estimate of pLOF variants, was $4 \times 10^{-5}$ for a cumulative MAF of 0.002. Patients with these defects are more likely to be challenged with live attenuated viral vaccines (e.g., first dose of MMR at 12 mo) and common viral infections (e.g., HSV-1 and influenza virus) before exposure to SARS-CoV-2. Only TLR7 deficiency has not been associated with other common viral infections, potentially accounting for the higher proportion of TLR7-deficient patients in our cohort than of patients with other recessive defects. Indeed, three of the five patients without TLR7 deficiency in our cohort had survived severe viral infections requiring hospitalization or intensive care before COVID-19 (P1, infection with MMR vaccine and influenza; P2, infection with influenza virus; and P3, influenza), whereas none of the TLR7-deficient patients had been hospitalized for viral infections before COVID-19 infection (Table 1). The viral illnesses in P1, P2, and P3 had not led to genetic and immunological studies. There is currently no accurate estimate of the incidence of critical pneumonia in SARS-CoV-2-infected children, but it is likely to be $\sim 0.01\%$, based on an IFR in children of $\sim 0.001\%$. The estimated cumulative frequency of recessive deficiency due to pLOF variants of the four genes is consistent with AR or XR inborn errors of type I IFN immunity being causal for COVID-19 pneumonia, with complete (e.g., probably IFNAR1 and STAT2 deficiencies) or incomplete (e.g., TLR7 and perhaps TYK2 deficiencies) penetrance, depending on the locus. Recessive defects of other loci governing type I IFN immunity may also be found in other children.

Enhanced SARS-CoV-2 replication in STAT2- and TYK2-deficient patients’ cells

We previously showed that the SV40-transformed fibroblasts (SV40 fibroblasts) of TLR3-, IRF7-, and IFNAR1-deficient patients cannot control SARS-CoV-2 infection normally in vitro (Zhang et al., 2020b), and that the pDCs of IRAK4-, UNC93B-, and TLR7-deficient patients cannot induce type I IFNs normally when challenged with SARS-CoV-2 in vitro (Asano et al., 2021; Onodi et al., 2021). We hypothesized that cells from STAT2- and TYK2-deficient patients might also be unable to restrict the replication of SARS-CoV-2 normally. We transduced SV40 fibroblasts with ACE2, which rendered them permissive to SARS-CoV-2 infection. We infected SV40 fibroblasts from a TYK2-deficient patient with the same genotype as P2–P4 (homozygous for P216fs*14) with SARS-CoV-2. We also infected SV40 fibroblasts from P1, a STAT2-deficient patient. We measured the intracellular expression of the viral nucleocapsid protein (N-protein) as an indicator of viral replication. Using healthy donor cells as positive controls, and cells from previously diagnosed patients with complete IFNAR1 and STAT2 deficiencies as negative controls, we found that cells from STAT2- and TYK2-deficient patients did not control viral replication normally (Fig. 4 A). Moreover, pretreatment of the cells with IFN-α2b blocked viral infection in healthy donor cells but not in patient cells (Fig. 4 A). We then measured ISGs (IFI14, MX1, and IFT27) induction in the SARS-CoV-2-infected cells by quantitative RT-PCR (qPCR). We found that cells from
STAT2- and TYK2-deficient patients failed to induce ISG production in response to SARS-CoV-2 infection or IFN-αβ pretreatment (Fig. 4 B). Thus, cells from STAT2- and TYK2-deficient patients were unable to control SARS-CoV-2 infection in a type I IFN-dependent manner in vitro. These findings further suggest that these deficiencies were causal for COVID-19 pneumonia in patients with either disorder.

Concluding remarks

Our findings suggest that three of the 14 known AR inborn errors of type I IFN immunity underlie COVID-19 pneumonia in ∼4% of children. A strong enrichment was observed for very rare (MAF <10−4) pLOF and missense variants, and for pLOF variants regardless of their MAF. A study of missense variants with higher frequencies might increase this proportion, but this would require a biochemical characterization of all variants in the general population, as previously performed for TLR7 (Asano et al., 2021). We also found XR TLR7 deficiency in ∼6% of children and 8.9% of boys with pneumonia. We provide evidence that recessive and complete defects at these four loci can underlie ∼10% of cases of COVID-19 pneumonia in hospitalized children, but the possible role of the other 11 loci in COVID-19 pneumonia remains unclear. Recessive complete defects at the IFNAR2, STAT1, and IRF9 (Levy et al., 2021) loci would also probably be causal, given the identification of patients with IFNAR1, TYK2, STAT2, and IRF7 deficiencies (Abolhassani et al., 2022; Khammoumhamdi et al., 2021; Zhang et al., 2020b; this report), as would defects at the TBK1 locus, given the previous report (Schmidt et al., 2021), and defects at the UNC93B1, MYD88, and IRAK4 loci, given the identification of patients with TLR7 deficiency (Asano et al., 2021). It is also probable that recessive defects of MDA5, TLR3, and TRIF may underlie COVID pneumonia in children. The high proportion of TLR7-deficient patients in the pediatric COVID-19 pneumonia cohort may reflect the narrow spectrum of viral infections in these patients and the XR inheritance of the disease. Accordingly, the apparent lack of IFNAR2, IRF9, and MDA5 defects may result from other life-threatening infections at an earlier stage of the lives of affected patients and their AR inheritance, whereas the apparent lack of AR STAT1, TLR3, and TRIF defects may also be due to the greater rarity of these defects, due in part to the occurrence of an AD form of these genetic defects.

The prevalence of AR disorders was 4.6% in the 108 unrelated children with COVID-19 pneumonia, with a significantly higher prevalence in patients born to consanguineous parents (with homozygosity rates >1%) than in patients not born to consanguineous parents (16 vs. 1.2%, Fisher’s exact test, P = 0.01), and 5.7% in the 70 unrelated children with critical COVID-19 pneumonia, much higher than the 0.6% of critical COVID-19 pneumonia cases in adults over the age of 16 yr or the 0.8% of patients with critical COVID-19 pneumonia ages 16–60 yr from the same international cohort (Zhang et al., 2020b). In addition, XR TLR7 deficiency was identified in 7% of the 71 unrelated male children with COVID-19 pneumonia, with no significant difference between male patients born to consanguineous parents and male patients born to non-consanguineous parents (20 vs. 7.7%, Fisher’s exact test, P = 0.27), and 6.1% of 49 unrelated male children with critical COVID-19 pneumonia, vs. 1.3% of adult males with critical pneumonia ages 16–60 yr (Asano et al., 2021). This higher proportion probably results from (a) the small number of patients with these inborn errors reaching adulthood undiagnosed, and (b) other risk factors, such as auto-Abs against type I IFN, which increase with age (Manry et al., 2022). However, the clinical penetrance of these four recessive type I IFN deficiencies for COVID-19 pneumonia probably increases with age and probably depends on the deficiency. It is predicted to be higher for STAT2 deficiency (unresponsive to both type I and III IFNs) than for IRF7 (inability to produce type I and III IFNs other than IFN-β) and IFNAR1 deficiencies (unresponsive to type I IFNs), and TLR7 deficiency is predicted to be the least penetrant (inability of pDCs to produce type I and III IFNs). TLR7 deficiency has already been shown to have a high, but incomplete, penetrance (Asano et al., 2021). Only one 5-yr-old child among the young relatives of the 12 index cases carried the LOF TLR7 variant; he remained asymptomatic upon SARS-CoV-2 infection (Fig. 1 C; Asano et al., 2021). Our findings here are thus consistent with predictions and previous reports.

Age itself is probably a major determinant of the penetrance of inborn errors, including the 15 recessive inborn errors studied here (Brodin, 2022). In populations naive for SARS-CoV-2, age is the major epidemiological risk factor for hospitalization or death from pneumonia, with the risk doubling every 5 yr of age, from childhood onward (O’Driscoll et al., 2021). The pediatric population is, therefore, generally considered “safe,” with an IFR of ∼0.001%, and a frequency of critical pneumonia thought to be on the order of 0.01%, but which remains to be estimated accurately (Knock et al., 2021; Le Vu et al., 2021). The risks of comorbidities and auto-Abs against type I IFNs both increase with age (Bastard et al., 2021a; Manry et al., 2022), whereas the levels of tonic type I IFN immunity in the respiratory tract decrease with age (Loske et al., 2021), and the production of type I IFN by pDCs is stronger in children than in adults (Splunter et al., 2019). These factors may both protect children and contribute to the age-dependent increase in the risk of COVID-19 pneumonia. Further studies are required to decipher the underlying mechanisms, but these findings suggest that both the penetrance and severity of COVID-19 for inborn errors of type I IFN immunity may be lower in children than in adults. It is tempting to speculate that the moderate pneumonia seen in children with TYK2 or TLR7 deficiency may have been severe or critical in adults with the same recessive disorder, whereas the severe pneumonia seen in children with TLR7 deficiency may have been critical in adults.

Our findings and previous reports suggest that impaired type I IFN immunity can underlie life-threatening COVID-19 pneumonia in patients of all ages. Auto-Abs against type I IFNs can be found in children and adults, particularly those >60 yr old. A role for auto-Abs neutralizing type I IFNs in children is attested by the high risk of COVID-19 pneumonia in children with autoimmune polyglandular syndrome type 1 (APS-1; Bastard et al., 2021e). Dominant inborn errors of type I IFN immunity can be found in adults, particularly those <60 yr old (Zhang et al., 2020b). It will be important to determine whether they are also found in children and, if so, at what frequency. Recessive inborn errors are
Figure 4. SARS-CoV-2 infection in patient cells. (A) Patient SV40 fibroblasts expressing ACE2 were pretreated with 1,000 IU/ml IFN-α2b or left untreated for 16 h and were then infected with SARS-CoV-2 for 72 h. N-protein and cell nuclei were stained with specific anti-N-protein antibody and Hoechst 33342, respectively. The percentage of cells positive for N-protein was determined automatically. We tested SV40 fibroblasts from P1 and a patient with the same type I IFN defect in children with COVID pneumonia.
found in adults under the age of 60 yr but are more frequent in children. Children with one of at least five known recessive inborn errors of type I IFN immunity (complete defects of STAT2, IFNAR1, TYK2, TLR7, and TBK1) are at high risk of developing COVID-19 pneumonia, including critical pneumonia. Recessive and complete defects of IRF7 (as suggested by studies of adult patients with critical COVID-19 pneumonia), IFNAR2, STAT1, STAT2, IRF9, and UNC93B1 (as suggested by other viral infections in children) probably predispose children to COVID-19 pneumonia with high penetrance. Penetrance may also be high for complete defects of TLR3, TRIF, and MDA5. Inborn errors of type I IFNs should be considered in children hospitalized for COVID-19. Personalized treatment in the first days of infection, including therapeutic type I IFN (Bastard et al., 2021b; Vinh et al., 2021) and monoclonal antibody therapy (Levy et al., 2021), should be considered in patients with defects upstream and downstream from type I IFN receptors, respectively (Zhang et al., 2022). The human genetic and immunological determinants of disease in other children remain to be discovered. Prime candidate genes include those governing the induction of or the response to type I IFNs (Schneider et al., 2021).

Materials and methods

Patients

This study included 112 pediatric patients hospitalized for COVID-19 pneumonia in Belgium, Brazil, the Czech Republic, Egypt, France, Hong Kong, Iran, Italy, Peru, Spain, Switzerland, Turkey, the United Arab Emirates, and the United States. Critical COVID-19 pneumonia was defined as critical disease in a patient with pneumonia, whether pulmonary with high-flow oxygen (>6 liters/min) or mechanical ventilation (CPAP, BIPAP, or intubation), or with septic shock or any other type of organ damage requiring ICU admission. This study also included patients with severe COVID-19 pneumonia, defined as pneumonia in a hospitalized patient requiring low-flow oxygen (<6 liters/min) treatment; moderate COVID-19 pneumonia, defined as pneumonia in a patient not requiring oxygen therapy; and mild COVID-19, defined as mild upper respiratory tract symptoms in a patient without pneumonia (Asano et al., 2021).

Written informed consent was obtained in the country of residence of the patients, in accordance with local regulations, and with institutional review board approval. Experiments were conducted in the United States, Sweden, Singapore, and France, in accordance with local regulations and with the approval of the institutional review board. Approval was obtained from the French Ethics Committee “Comité de Protection des Personnes,” the French National Agency for Medicine and Health Product Safety, the “Institut National de la Santé et de la Recherche Médicale,” in Paris, France (protocol no. C10-13), and the Rockefeller University Institutional Review Board in New York (protocol no. JCA-0700).

Next-generation sequencing

Genomic DNA was extracted from whole blood. The whole exome (n = 802) or whole genome (n = 534) was sequenced for all 1,336 patients included, at several sequencing centers, including the Genomics Core Facility of the Imagine Institute (Paris, France), the Yale Center for Genome Analysis (New Haven, CT), the New York Genome Center (New York, NY), the American Genome Center (Uniformed Services University of the Health Sciences Bethesda, MD), and the Genomics Division-ITER of the Canarian Health System sequencing hub (Canary Islands, Spain).

For WES, libraries were generated with the Twist Bioscience kit (Twist Human Core Exome Kit), the xGen Exome Research Panel from Integrated DNA Technologies (IDT xGen), the Agilent SureSelect V6 kit, the Agilent SureSelect V7 kit or the SeqCap EZ MedExome kit from Roche, and the Nextera Flex for Enrichment-Exome kit (Illumina). Massively parallel sequencing was performed on a HiSeq4000 or NovaSeq6000 system (Illumina). For WES analysis, performed at CNAG (Barcelona, Spain), capture was performed with the SeqCap EZ Human Exome Kit v3.0 (Roche Nimblegen) and 100-bp paired-end read sequences were obtained on a HiSeq 2000–4000 platform (Illumina). For the OSR Italian cohort, WES was performed with the Agilent SureSelect V7 kit on a NovaSeq6000 system (Illumina).

For WGS on patients of the Italian cohort (the American Genome Center), genomic DNA samples were dispensed into the wells of a Covaris 96 microTUBE plate (1,000 ng per well) and sheared with a Covaris LE220 Focused ultrasonicator, at settings targeting a peak size of 410 bp (t:78; Duty:18; PIP:450; 200 cycles). Sequencing libraries were generated from fragmented DNA with the Illumina TruSeq DNA PCR-Free HT Library Preparation Kit, according to the manufacturer’s protocol but with minor modifications for automation (Hamilton STAR Liquid Handling System), with IDT for Illumina TruSeq DNA UD Index (96 indices, 96 samples) adapters. Library size distribution was assessed and the absence of free adapters or adapter dimers was checked by automated capillary gel electrophoresis (Advanced Analytical Fragment Analyzer). Library concentration was determined by qPCR with the KAPA qPCR Quantification Kit (Roche Light Cycler 480 Instrument II). Sequencing libraries were normalized and combined as 24-plex pools and quantified as above, before dilution to 2.9 nM and sequencing on an Illumina NovaSeq 6000 with the S4 Reagent Kit (300 cycles) and 151 + 8 x 8 + 151 cycle run parameters. Primary sequencing data were demultiplexed with the Illumina HAS2.2 pipeline, and
sample-level quality control was performed for base quality, coverage, duplicates, and contamination (FREE MIX <0.05 by Verify Bam ID).

We used the Genome Analysis Software Kit (GATK; v3.4-46 or 4) best-practice pipeline to analyze our WES data (DePristo et al., 2011). We aligned the reads obtained with the human reference genome (hg19), using the maximum exact matches algorithm in the Burrows–Wheeler Aligner (Li and Durbin, 2009). PCR duplicates were removed with Picard tools (http://picard.sourceforge.net). The GATK base quality score recalibrator was applied to correct sequencing artifacts. Genotyping was performed with GATK GenotypeGVCFs in the interval intersecting all the capture kits ±50 bp. Sample genotypes with a coverage <8, a genotype quality <20, or a ratio of reads for the least covered allele (reference or variant allele) over the total number of reads covering the position (minor read ratio) <20% were filtered out. We filtered out variant sites that (a) fell in low-complexity or decoy regions, (b) were multiallelic with more than four alleles, (c) had >10% missing genotypes in our cohort, and (d) spanned >15 nucleotides. Variant effects were predicted with the Ensembl Variant Effect Predictor (McLaren et al., 2016) and the Ensembl GRCh37.75 reference database, retaining the most deleterious annotation obtained from Ensembl protein coding transcripts overlapping with RefSeq transcripts.

Copy number variant detection
We searched for deletions in the 15 genes of interest, using the NGS data and the HMZDelFinder-opt (Bigio et al., 2021) and MANTA (Chen et al., 2016) algorithms.

Statistical analysis
We performed an enrichment analysis focusing on 15 candidate genes, on our cohort of 112 pediatric patients with COVID-19 pneumonia, and 1,224 children and adults with asymptomatic or paucisymptomatic infection. We considered variants that were predicted to be LOF or missense and had an MAF <0.0001 (gnomAD v2.1.1). We searched for recessive defects by looking at homozygous and compound heterozygous variants as well as rare homozygous deletions. The quality of the read alignments and phase, for potential compound heterozygotes, was reviewed with the Integrative Genomics Viewer (Robinson et al., 2011). We compared the proportion of patients and controls carrying at least one potential recessive defect in Firth bias-corrected logistic likelihood ratio tests implemented in the logistR package. In Firth’s regression, a penalty term is assigned to the standard maximum likelihood function used to estimate the parameters of a logistic regression model (Firth, 1993). Firth’s regression can handle genes for which there are no carriers among cases or controls. With no covariates, this corresponds to adding 0.5 to every cell of a 2 × 2 table of allele counts vs. case-control status. We accounted for ethnic heterogeneity by including the first five principal components of the PCA in Firth’s logistic regression model. Analyses were also adjusted for sex. We checked that our adjusted burden test was well calibrated by also analyzing the enrichment in rare (MAF <0.0001) homozygous synonymous variants. We performed PCA with Plink v1.9 software on WES and WGS data, with the 1000 Genomes Project phase 3 public database as a reference, using >15,000 exonic variants with MAF >0.01 and call rate >0.99. We estimated pairwise relatedness between patients and controls using the related option of King software (Manichaikul et al., 2010) and screened for pairs of related individuals, up to the third degree (kinship ≥0.0442). We also estimated the homozygosity rate of the patients and controls from the WES data as the proportion of the autosomal genome in runs of homozygosity (Belkadi et al., 2016). We identified runs of homozygosity with PLINK (Purcell et al., 2007) using a 1,000-kb window and 50 single-nucleotide variations in the window. For this analysis, we used ~167,000 single-nucleotide variations with a gnomAD frequency >0.05.

In vitro assays of STAT2 production and function
HEK293T cells were used to seed 6-well plates and were transfected with pCMV-STAT2 WT/mutant variants for 24 h before stimulation with 10,000 U/ml IFN-α2a for 30 min (130-093-874, hIFNa2a; Miltenyi Biotec). The cells were lysed in radioimmunoprecipitation assay buffer, and Western blotting was performed to detect total and phosphorylated STAT2. β-Actin was used as a loading control.

U6A fibrosarcoma cells were transfected with pCMV-STAT2 WT/mutant variants for 24 h before being stimulated with 10,000 U/ml IFN-α2A for 6 h. RNA was extracted with Trizol and the PureLink RNA extraction kit and reverse-transcribed with the Superscript Vilo cDNA production kit. Real-time PCR was performed with the SYBR green kit for IFIT1, IFI27, and RSAD2, with specific primers, and GAPDH was used as the housekeeping gene. Results are expressed according to the ΔΔCt method, where Ct is threshold count, as described by the kit manufacturer.

Functional assay of IFN responsiveness in human fibroblasts
Primary cultures of human fibroblasts were established from skin biopsy specimens from patients or healthy controls. SV40 fibroblasts were used to seed a 6-well plate and were incubated for 18 h before stimulation with 10,000 U/ml IFN-γ for 6 h. The cells were then lysed in radioimmunoprecipitation assay buffer, and Western blotting was performed to detect total and phosphorylated STAT1 and STAT2. GAPDH was used as a loading control.

 Luciferase reporter assays for TLR7 functional testing
HEK293T cells, which have no endogenous TLR7 expression, were transfected with the pCMV6 vector bearing WT or variant TLR7 (50 ng), the reporter construct pGL4.32 (100 ng), and an expression vector for Renilla luciferase (10 ng), with the X-tremeGENE 9 DNA Transfection Reagent kit (Sigma-Aldrich). The pGL4.32 (luc2P/NF-κB-RE/Hygo; Promega) reporter vector contains five copies of the NF-κB-responsive element (NF-κB-RE) linked to the luciferase reporter gene luc2P. After 24 h, the transfected cells were left unstimulated or were stimulated for 24 h with 1 μg/ml R848 (Resquimod), for activation via TLR7/8 (InvivoGen). Relative luciferase activity was then determined by normalizing the values, using the firefly:Renilla luciferase signal ratio.

Western blotting was performed to assess the amounts of protein produced for the TLR7 variants. For whole-cell extracts,
the cells were lysed by incubation in the following buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 1% NP-40), supplemented with a mixture of protease inhibitors (Sigma-Aldrich), for 30 min at 4°C. The lysates were then centrifuged at 21,000 g for 20 min at 4°C. The supernatants were processed directly for Western blotting. Western blotting was performed on 10 µg of total extract from transfected HEK293T cells, with monoclonal antibodies specific for the leucine-rich repeats at the N-terminus of the human TLR7 protein (Cell Signaling Technology) or for amino acid 1,000 at the C-terminus of the human TLR7 protein (Abcam).

**Luciferase reporter assays for MDA5 functional testing**

The detailed method has been described elsewhere (Lamborn et al., 2017). In brief, HEK293T cells (80,000 cells/well) were transfected with pIFNB-GL3 (200 ng), pRL-TK (20 ng), and MDA5 or EV (50 ng) at a 1:4 DNA/polyethyleneimine ratio and used to seed 96-well plates. The cells were then stimulated, 24 h after transfection, with 2 µg/ml poly(I:C) in the presence of Lipofectamine 2000 (Thermo Fisher Scientific). After stimulation, cells were washed once in PBS and lysed in 200 µl of 1× passive lysis buffer (Promega). Dual luciferase assays were performed on a microplate reader (BMG Labtech Fluostar Omega) in accordance with the manufacturer’s protocol (Promega). Activity was calculated as a percentage of WT MDA5, by dividing the normalized firefly:Renilla luciferase ratio for each variant by the normalized WT value and multiplying by 100, and was plotted with Prism 8 software (GraphPad).

**Luciferase reporter assays for IRF7 functional testing**

The method has been described in detail elsewhere (Zhang et al., 2020b). HEK293T cells were cotransfected with a mixture of the IFN-β-firefly luciferase reporter plasmid, the pRL-TK-Renilla luciferase plasmid, and the pCDNA3-IRF7 plasmid. Cells were incubated for 24 h and were then either left untreated or infected with Sendai virus (20 hemagglutination units/well) for another 24 h. Reporter activity was measured with the Dual-Luciferase Reporter Assay System. Firefly luciferase activity was normalized against Renilla luciferase activity. IRF7 expression levels were measured by Western blotting (anti-IRF7 antibody: Cell Signaling; anti-FLAG antibody: Sigma-Aldrich).

**SARS-CoV-2 infection experiments**

The SARS-CoV-2 NYC isolate (GenBank accession no. OM345241) was obtained from a de-identified patient. The virus isolate was amplified through 6–7–d passages in Caco-2 cells at 37°C. After each passage, virus-containing supernatant was harvested, clarified by centrifugation (3,000 g for 10 min), and filtered through a disposable vacuum filter system with 0.22-µm pores. The passage 3 stock, used in this study, had a titer of 3.4 × 10^21 PFU/ml determined on Vero E6 cells with a 1% methylcellulose overlay, as described in a previous study (Mendoza et al., 2020). Human SV40 fibroblasts were stably transduced with pTRIP-CD271-2A-ACE2 and positively selected to obtain >90% CD271+ cells (130-099-023; Miltenyi Biotec). Cells were used to seed 96-well plates at a density of 7,000 cells per well, with or without 0.1 µl/well SARS-CoV-2 16 h later, in 110 µl/well total volume, and were spun for 5 min at 500 g. Four replicate infections were performed (separate wells). At 72 hpi, the cells were fixed with neutral buffered formalin at a final concentration of 10%, stained for SARS-CoV-2 with an anti-N-protein antibody at a dilution of 1:3,000 (GTX135357; GeneTex), then with an Alexa Fluor 647–conjugated secondary antibody (A-21245; Invitrogen) and 1 µg/ml Hoechst 33342 (H3570; Invitrogen). Plates were imaged with ImageXpress micro XL and analyzed with MetaXpress (Molecular Devices).

**ISG induction in SARS-CoV-2–infected cells**

ISG (IFIT1, MXI, and IFI27) induction was measured by qPCR. In brief, a parallel experiment was performed as described above, except that, rather than staining for immunofluorescence analysis, we lysed the cells and extracted total RNA (Quick-RNA micro prep kit; Zimo Research). We then synthesized cDNA with random hexamers (SuperScript III First-strand cDNA synthesis system; Invitrogen). Hs00356631_g1 (Thermo Fisher Scientific), MXI (Hs00895608_ml; Thermo Fisher Scientific), IFI27 (Hs01086373_g1; Thermo Fisher Scientific), and the housekeeping gene GUSB (β-glucuronidase, 4310888E; Thermo Fisher Scientific) were mixed with cDNA, and their levels were determined (QuantStudio 3 Real-Time PCR system; Applied Biosystems).

**Acknowledgments**

We thank the patients’ families for agreeing to participate in our research.

The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute; the Rockefeller University; the St. Giles Foundation; the National Institutes of Health (NIH; R01AI088364 and R01AI63029); the National Center for Advancing Translational Sciences; NIH Clinical and Translational Science Award program (UL1 TR001866); a Fast Grant from Emergent Ventures; the Mercatus Center at George Mason University; the Yale Center for Mendelian Genomics; the GSP Coordinating Center funded by the National Human Genome Research Institute (U54HG006504 and U24HG008956); the Yale High Performance Computing Center (S10OD018521); the Fisher Center for Alzheimer’s Research Foundation; the JPB Foundation; the Meyer Foundation; the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAIHU-01); the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID); the French Foundation for Medical Research (EQU201903007798); the ANR GenMISC (ANR-21-COV-039) ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AABINFVOC (ANR-20-CO11-0001) projects; the European Union’s Horizon 2020 research and innovation program under grant agreement no. 824110 (EASi-genomics); the Square Foundation; Grandir—Fonds de solidarité pour l’enfance; Fondation du Souffle; the SCOR Corporate Foundation for Science; The French Ministry of Higher Education, Research, and Innovation (MESR-COVID-19); Institut National de la Santé et de la Recherche Médicale (INSERM); REACTing-INSERM; and the University
of Paris. Work in the Laboratory of Virology and Infectious Disease was supported by NIH grants FOAI138398-S1, 2U19AI111825, R01AI091707-10S1, and R01AI161444; a George Mason University Fast Grant; the G. Harold and Leila Y. Mathers Charitable Foundation; the Meyer Foundation; and the Bawd Foundation. J. Le Pen was supported by the Francois Wallace Monahan Postdoctoral Fellowship at The Rockefeller University and the European Molecular Biology Organization Long-Term Fellowship (ALTF 380-2018). P. Bastard was supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). H.C. Su and H. Jing are supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. G. Novelli and A. Novelli from the COVID Human Genetic Effort are supported by Regione Lazio (Research Group Projects 2020) no. A0375-2020-36663, Gecobiomark. I. Meyts is a Senior Clinical Investigator at the Research Foundation—Flanders and is supported by the CSL Behring Chair of Primary Immunodeficiencies, by the CSL-Behring Research Grant, by the KU Leuven CI grant C16/18/007, by a VIB GC PID grant, by the FWO grants G0C8517N, G0B5120N, and GOE8420N and by the Jeffrey Modell Foundation. This project has received funding from the European Research Council under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948959). This work is supported by ERN-RITA. S. Delafontaine is supported by personal FWO grant IF4F42IN. L. Renia and L.F.P. Ng were supported by the Singapore National Medical Research Council COVID-19 Research Fund (COVID19RF-001; COVID19RF-0008; COVID19RF-060) and A*STAR COVID-19 research funding (H/20/04/g1/006). The Canarian Sequencing Hub is funded by Instituto de Salud Carlos III (COV20_01333 and COV20_01334), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”).

Author contributions: Q. Zhang, D. Matteuzzo, J. Le Pen, D. Lee, L. Moens, T. Asano, J. Bohlen, Z. Liu, M. Moncada-Velez, Y. Kendir-Demirkol, H. Jing, L. Bizien, A. Marchal, H. Abolhassani, G.I. Bayhan, A. Kiyikim, S. Hancerli, L.F.P. Ng, and A. Cobat performed experiments and contributed to data curation. Q. Zhang, S. Delafontaine, G. Buiocci, S. Keles, F. Haerynck, B. Florkin, N. Hatipoglu, T. Ozcelik, G. Morelle, M. Zatz, L.F.P. Ng, D.C. Lye, B.E. Young, Y.-S. Leo, C.L. Dalgaard, R.P. Lifton, L. Renia, I. Meyts, E. Jouanguy, L. Hammarström, Q. Pan-Hammarström, B. Boisson, P. Bastard, H.C. Su, S. Boisson-Dupuis, L. Abel, C. M. Rice, S.-Y. Zhang, A. Cobat, and J.-L. Casanova contributed to the funding, resources, and investigation of patients. Q. Zhang and J.-L. Casanova wrote the draft, and all co-authors contributed to the editing of the manuscript. All co-authors contributed to the scientific discussion.

Disclosures: B.E. Young reported personal fees from Sanofi, Gilead, Roche, Astra-Zeneca, and Novacryte outside the submitted work. R.P. Lifton is a member of the board of directors of Roche and its subsidiary Genentech. I. Meyts reported grants from CSL-Behring outside the submitted work. J.-L. Casanova reported a patent to PCT/US2021/042741 pending. No other disclosures were reported.
Diebold, B., Y. Seeleuthner, G. Kerner, M. Migaud, J. Rosain, B. Boisson, C. Nasca, A. Puel, J. Bustamante, J.L. Casanova, et al. 2021. Detection of homozygous complex or partial exon deletions by whole-exome sequencing. NAR Genom Bioinform. 3:lgab037. https://doi.org/10.1093/ncomms/lgab037

Boisson-Dupuis, S., N. Ramirez-Alejo, Z. Li, E. Patin, G. Rao, G. Kerner, C.K. Lim, D.N. Kremetsrov, N. Hernandez, C.S. Ma, et al. 2018. Tuberculosis and impaired IL-23-dependent IFN-gamma immunity in humans homozygous for a common TYK2 missense variant. Sci. Immunol. 3:eaa4714. https://doi.org/10.1126/sciimmunol.aau8714

Bravo Garcia-Morato, M., A. Calvo Apalategi, L.Y. Bravo-Gallego, A. Blazquez Bravo, M. Simon-Fuentes, J.V. Garmendia, A. Mendez Echevarria, T. Del Rosal Rabes, A. Dominguez-Soto, E. Lope-Granados, et al. 2019. Impaired control of multiple viral infections in a family with complete IRF3 deficiency. J. Allergy Clin. Immunol. 144:309–312.e10. https://doi.org/10.1016/j.jaci.2019.02.019

Brodin, P. 2021. Immune determinants of COVID-19 disease presentation and severity. Nat. Med. 27:28–33. https://doi.org/10.1038/s41591-020-01022-w

Brodin, P. 2022. SARS-CoV-2 infections in children: Understanding diverse outcomes. Immunity. 55:201–209. https://doi.org/10.1016/j.immuni.2022.01.014

Burns, C., A. Cheung, Z. Stark, S. Choo, L. Downie, S. White, R. Conyers, and T. Cole. 2016. A novel presentation of homozygous loss-of-function STAT1 mutation in an infant with hyperinflammation. A case report and review of the literature. J. Allergy Clin. Immunol. 2016. 4:777–779. https://doi.org/10.1016/j.jaci.2016.02.015

Casanova, J.L., and L. Abel. 2021. Mechanisms of viral inflammation and disease in humans. Science. 374:1080–1086. https://doi.org/10.1126/science.abj7965

Casrouge, A., S.Y. Zhang, C. Eidschenschenk, E. Jouanguy, A. Chapgier, C. Eidenschenk, P. Eid, et al. 2021. Impaired recombination in human antiviral type III interferon responses. J. Allergy Clin. Immunol. 137:1591–1591.e5. https://doi.org/10.1016/j.jaci.2021.05.050

Goa, D., M.J. Ciancanelli, P. Zhang, O. Harschitz, V. Bondet, M. Hasek, J. Chen, X. Yu, I. Atan, A. cobat, et al. 2021. TLR3 controls constitutive IFN-beta antiviral immunity in human fibroblasts and cortical neurons. J. Clin. Invest. 131:154529. https://doi.org/10.1172/JCI154529

Giardine, G., V. Gallo, D. Somma, E.G. Farrow, I. Thiffault, R. D. Assante, V. Donorizio, M. Pacolla, A. Leonardi, et al. 2016. Targeted next-generation sequencing revealed MYD88 deficiency in a child with chronic yenisurans and granulomatous lymphadenitis. J. Allergy Clin. Immunol. 137:1591–1591.e4. https://doi.org/10.1016/j.jaci.2015.09.050

Gotche, C.F. Hatton, L. Truong, Z. Klimova, V. Kanderaov, M. Fefjkova, A. Grainger, V. Bigley, J. Retten, D. Mitra, et al. 2020. A novel case of homozygous IFNAR1 deficiency with haemophagocytic lymphohistiocytosis. Blood. 2020. 208:1–8. https://doi.org/10.1182/blood.2020.208312. https://doi.org/10.1182/blood.2020.208312

Hambleton, S., S. Goodburn, D.F. Young, P. Dickinson, S.M. Mohamed, M. Valappil, N. Mcgovner, A.J. Cant, S.J. Hackett, P. Ghazal, et al. 2013. STAT2 deficiency and susceptibility to viral illness in humans. Proc. Natl. Acad. Sci. USA. 110:3053–3058. https://doi.org/10.1073/pnas.1220098110

Heil, F., A. Hemti, H. Hochrein, F. Ambeneger, C. Kirschning, A. Ackira, L. Lipford, H. Wagner, and S. Bauer. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 303:1526–1529. https://doi.org/10.1126/science.1093620

Hernandez, N., G. Bucciol, L. Moens, J. Le Pn, M. Shahroeei, E. Goudouris, A. Shirkani, M. Changi-Ashtiani, H. Roozl-Nadz, E.H. Sayar, et al. 2019. Inherited IFNAR1 deficiency in otherwise healthy patients with acute respiratory distress due to severe acute respiratory syndrome coronavirus 2 infection. J. Pediatr. 216:2057–2070. https://doi.org/10.1016/j.jpeds.20182295

Hernandez, N., I. Melki, H. Jing, T. Habib, S.S.Y. Huang, J. Danielson, R. Chen, and L. Abel. 2021. Life-threatening influenza, hemophagocytic lymphohistiocytosis and probable vaccine-strain varicella in a novel case of homozygous STAT2A deficiency. Front. Immunol. 11:624415. https://doi.org/10.3389/fimmu.2020.624415

Fuchs, S., P. Kaiser-Labusch, J. Bank, S. Ammann, A. Kolb-Kokocinski, C. Edelbusch, H. Omran, and S. Ehl. 2016. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses. Eur. J. Immunol. 46:2639–2649. https://doi.org/10.1002/eji.201646519

DePristo, M.A., E. Banks, R. Poplin, K.V. Garimella, J.R. Maguire, C. Hartl, D. Heckel, D.R. De Veal, R. Flicek, I.Z. Moshen, S. Al-Jumaah, K. Yang, A. Chapghier, C. Eidschenschenk, P. Eid, et al. 2003. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat. Genet. 33:388–391. https://doi.org/10.1038/ng1097

Zhang et al.

Type I IFN defect in children with COVID pneumonia

https://doi.org/10.1016/j.jem.20220131
Heterozygous TYK2 mutations underlie primary immunodeficiency

Type I IFN defect in children with COVID pneumonia

with T-cells lymphopenia. Sci. Rep. 8:6956. https://doi.org/10.1038/s41598-018-25266-8

Nishiyama, S., Y. Kobayashi, H. Ohnishi, K. Moriya, M. Tsumura, S. Sakata, Y. Mizoguchi, H. Takada, Z. Kato, V. Sancho-Shimizu, et al. 2021. IRAK4 deficiency presenting with anti-NMDAR encephalitis and HIV-1 reactivation. J. Clin. Immunol. 41:125-135. https://doi.org/10.1007/s10875-020-01388-y

O’Driscoll, M., G. Ribeiro Dos Santos, L. Wang, D.A.T. Cummins, A.S. Azman, J. Faureau, A. Fontanet, S. Cauchemez, and H. Salje. 2021. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 990:140-145. https://doi.org/10.1038/s41586-020-2918-0

Onodi, F., L. Bonnet-Madin, L. Meertens, L. Karpf, Y.S. Chang, C. Picard, A. Puel, E. Jouangy, Q. Zhang, et al. 2021. SARS-CoV-2 induces human plasmacytoid dendritic cell diversification via UNC93B and IRAK4. J. Exp. Med. 218:e20210387. https://doi.org/10.1084/jem.20210387

Pessoa, N.L., A.A. Bentes, A.L. de Carvalho, T.B. de Souza Silva, P.A. Alves, E.V. de Sousa Reis, T.A. Rodrigues, E.G. Kroon, and M.A. Campos. 2021. Case report: Hepatitis in a child infected with SARS-CoV-2 presenting toll-like receptor 2 Gln1Leu single nucleotide polymorphism. Viral J. 18: 1. https://doi.org/10.1186/s12895-021-01656-3

Picard, C., A. Puel, M. Bonnet, C.L. Kui, J. Bustamante, K. Yang, C. Soudais, S. Dupuis, J. Feinberg, C. Fieschi, et al. 2003. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 299:2076-2079. https://doi.org/10.1126/science.1081902

Pierce, C.A., P. Preston-Hurlburt, Y. Dai, C.B. Aschner, N. Cheshenko, B. Galen, S.J. Garforth, N.G. Herrera, R.K. Junga, N.C. Morano, et al. 2020. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Sci. Transl. Med. 12:eab4d5487. https://doi.org/10.1126/scitranslmed.ab4d5487

Pierce, C.A., S. Sy, B. Galen, D.Y. Goldstein, E. Orner, M.J. Keller, K.C. Herold, and B.C. Herold. 2021. Natural mucosal barriers and COVID-19 in children. JCI Insight. 6:e148694. https://doi.org/10.1172/jci.insight.148694

Porcell, S., B. Neale, K. Todd-Brown, L. Thomas, M.A.R. Ferreira, D. Brender, J. Maller, P. Sklar, P.I.W. de Bakker, M.J. Daly, et al. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. Ann. Hum. Genet. 81:559–575. https://doi.org/10.1016/j.ajhg.2007.02.002

Roebner, J.T., H. Thorvaldsdottir, W. Winkler, M. Gutmann, E.S. Lander, G. Getz, and J.P. Mesirov. 2011. Integrative genomics viewer. Nat. Biootechnol. 29:24–26. https://doi.org/10.1038/nbt.1975

Sancho-Shimizu, V., R. Perez de Diego, L. Lorenzo, R. Halwani, A. Alangari, E. Israelsson, S. Fabrega, A. Cardon, J. Malenku, M. Tatematsu, et al. 2011. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J. Clin. Invest. 121:4889–4902. https://doi.org/10.1172/JCI59259

Sarrafzadeh, S.A., M. Mahloojirad, J.L. Casanova, M. Badalzadeh, J. Bustamante, S. Boisson-Dupuis, Z. Pourpak, M. Nourizadeh, and M. Moin. 2020. A new patient with inherited TYK2 deficiency. J. Clin. Immunol. 40:232–235. https://doi.org/10.1007/s10875-019-00713-5

Schmidt, A., S. Peters, A. Knaus, H. Sabir, F. Hamsen, C. Maj, F. Fazaa, S. Sivalingam, O. Savchenko, A. Mantri, et al. 2021. TBK1 and TNFRSF13B mutations and an autoinflammatory disease in a child with lethal COVID-19. NPJ Genom. Med. 6:55. https://doi.org/10.1038/s41525-021-0079-w

Schneider, W.M., J.M. Luna, H.H. Hoffmann, F.J. Sanchez-Rivera, and R.R. Montgomery. 2013. Age-dependent dysregulation of innate immunity. Proc. Natl. Acad. Sci. USA. 110:10939–10944. https://doi.org/10.1073/pnas.1304793110

Shaw, A.C., D.R. Goldstein, and R.R. Montgomery. 2013. Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 13:875–887. https://doi.org/10.1038/nri3540

Solaire, X., G. Vargas-Parra, G.J. van der Made, A. Simons, J. Schuurs-Hoefsloeymakers, A. Antoli, J. Del Valle, G. Rocamora-Blanch, F. Setien, M. Esteller, et al. 2021. Genetic screening for TLR7 variants in young and adult patients. NPJ Genom. Med. 6:55. https://doi.org/10.1038/s41525-021-0079-w

Schulze, L., and A.C. Aschenbrenner. 2021. COVID-19 and the human innate immune system. Cell. 184:1671–1692. https://doi.org/10.1016/j.cell.2020.06.006

Zhang et al. Type 1 IFN defect in children with COVID pneumonia

Journal of Experimental Medicine

https://doi.org/10.1084/jem.20220131
Stark, G.R., and J.E. Darnell Jr. 2012. The JAK-STAT pathway at twenty. Immunity. 36:503–514. https://doi.org/10.1016/j.immuni.2012.03.013

Taft, J., M. Markson, D. Legarda, R. Patel, M. Chan, L. Malle, A. Richardson, C. Gruber, M. Martin-Fernandez, G.M.S. Mancini, et al. 2021. Human TBK1 deficiency leads to autoinflammation driven by TNF-induced cell death. Cell. 184:4447–4463.e20. https://doi.org/10.1016/j.cell.2021.07.026

Tangye, S.G., W. Al-Herz, A. Bousfiha, C. Cunningham-Rundles, A. Ettzioni, J.L. Franco, S.M. Holland, C. Klein, T. Morio, et al. 2020. Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee. J. Clin. Immunol. 40:24–64. https://doi.org/10.1007/s10875-019-00737-x

Tangye, S.G., W. Al-Herz, A. Bousfiha, C. Cunningham-Rundles, J.L. Franco, S.M. Holland, C. Klein, T. Morio, E. Oksenhendler, C. Picard, et al. 2021. The ever-increasing array of novel inborn errors of immunity: An interim update by the IUIS committee. J. Clin. Immunol. 41:666–679. https://doi.org/10.1007/s10875-021-00980-1

Telenti, A., A. Arvin, L. Corey, D. Corti, M.S. Diamond, A. Garcia-Sastre, R.F. Garry, E.C. Holmes, P.S. Pang, and H.W. Virgin. 2021. After the pandemic: Perspectives on the future trajectory of COVID-19. Nature. 596:495–504. https://doi.org/10.1038/s41586-021-03792-w

van der Made, C.I., A. Simons, J. Schuurs-Hoeijmakers, G. van den Heuvel, T. Mantere, S. Kersten, R.C. van Deuren, M. Steehouwer, S.V. van Reijmersdal, M. Jaeger, et al. 2020. Presence of genetic variants among young men with severe COVID-19. JAMA. 324:663–673. https://doi.org/10.1001/jama.2020.13719

Vinh, D.C., L. Abel, P. Bastard, M.P. Cheng, A. Condino-Neto, P.K. Gregersen, F. Haerynck, M.P. Cicalese, D. Hagin, P. Soler-Palacin, et al. 2021. Harnessing type I IFN immunity against SARS-CoV-2 with early administration of IFN-β. J. Clin. Immunol. 41:1425–1442. https://doi.org/10.1007/s10875-021-01068-6

von Bernuth, H., C. Picard, Z. Jin, R. Pankla, H. Xiao, C.L. Ku, M. Chrabieh, I.B. Mustapha, P. Ghandil, Y. Camcioglu, et al. 2008. Pyogenic bacterial infections in humans with MyD88 deficiency. Science. 321:691–696. https://doi.org/10.1126/science.1158298

Zhang, Q., P. Bastard, A. Bolze, E. Jouanguy, S.Y. Zhang, COVID Human Genetic Effort, A. Cobat, L.D. Notarangelo, H.C. Su, L. Abel, and J.L. Casanova. 2020a. Life-threatening COVID-19: Defective interferons unleash excessive inflammation. Med. 1:14–20. https://doi.org/10.1016/j.medj.2020.12.001

Zhang, Q., P. Bastard, COVID Human Genetic Effort, A. Cobat, and J.L. Casanova. 2022. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 603:587–598. https://doi.org/10.1038/s41586-022-04447-0

Zhang, Q., P. Bastard, Z. Liu, J. Le Pen, M. Moncada-Velez, J. Chen, M. Ogishi, I.K.D. Sabli, S. Hodeib, C. Korol, et al. 2020b. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 370:1037–1038. https://doi.org/10.1126/science.abf1700

Zhang, S.Y., E. Jouanguy, S. Ugolini, A. Smahi, G. Elain, P. Romero, D. Segal, V. Sancho-Shimizu, L. Lorenzo, A. Puel, et al. 2007. TLR3 deficiency in patients with herpes simplex encephalitis. Science. 317:1522–1527. https://doi.org/10.1126/science.1139522
List of COVID Human Genetic Effort authors

Laurent Abel1, Hassan Abolhassani2, Alessandro Aiuti3, Ozge Metin Akcan4, Saleh Al-Muhsein5, Fahd Al-Mulla6, Gulsum Alkan7, Mark S. Anderson8, Evangelos Andreakos9, Andrés A. Arias10, Jalila El Bakkouri11, Hagit Baris Feldman12, Alexandre Belot13, Catherine M. Biggs14, Dusan Bogunovic15, Alexandre Bolze16, Anastasiia Bondarenko17, Ahmed A. Bousfiha18, Sefika Elmas Bozdemir19, Petter Brodin20, Yenan Bryceson21, Carlos D. Bustamante22, Manish J. Butte23, Giorgio Casari24, John Christodoulou25, Roger Colobran26, Antonio Condino-Neto27, Stefan N. Constantinescu28, Megan A. Cooper29, Clifton L. Dalgard30, Murkesh Desai31, Beth A. Drolet32, Jamila El Baghdadi33, Melike Emiroglu7, Emine Hafize Erdeniz34, Sara Espinosa-Padilla35, Jacques Fellay36, Carlos Flores37, José Luis Franco38, Antoine Froidure39, Peter K. Gregersen40, Bodo Grimbacher41, Belgin Gulhan42, Filomeen Haerynck43, David Hagin44, Rabih Halwani45, Lennart Hammarström46, James R. Heath47, Sarah E. Henrickson48, Elena W.Y. Hsieh49, Eystein Husebye50, Kohsuke Imai51, Yuval Itan52, Petr Jabandziev53, Erich D. Jarvis54, Timokratis Karamitros55, Adem Karbuz56, Kai Kisand57, Cheng-Lung Ku58, Yu-Lung Lau59, Yun Ling60, Carrie L. Lucas37, Tom Maniatis62, Davood Mansouri63, László Maródi64, Ayse Metin42, Isabelle Meyts65, Joshua D. Milner66, Kristina Mironska67, Trine H. Mogensen68, Tomohiro Morio69, Lisa F.P. Ng70, Luigi D. Notarangelo71, Antonio Novelli72, Giuseppe Novelli73, Cliona O’Farrelly74, Satoshi Okada75, Keisuke Okamoto76, Şadiye Kübra Tüter Öz7, Tayfun Ozcelik77, Qiang Pan-Hammarström46, Maria Papadaki9, Jean W. Pape78, Aslinur Ozkaya Parlakay79, Rebeca Perez de Diego80, David S. Perlin81, Graziano Pesole82, Anna M. Planas83, Petra Pokorna84, Carolina Prando85, Aurora Pujol86, Lluis Quintana-Murci87, Sathishkumar Ramaswamy88, Laurent Renia70, Igor Resnick90, Jacques G. Rivière90, Carlos Rodríguez-Gallego91, Vanessa Sancho-Shimizu92, Anna Sediva93, Mikko R.J. Seppänen94, Mohammed Shahrooei95, Anna Shcherbina96, Katerina
Slaba53, Ondrej Slaby97, Andrew L. Snow98, Pere Soler-Palacín99, Lien De Somer100, András N. Spaan101, Ivan Tancevski102, Stuart G. Tangye103, Ahmad Abou Tayoun88, Dimitris Thanos105, Stuart E. Turvey104, K M Furkan Uddin105, Mohammed J. Uddin106, Diederik van de Beek107, François Vermeulen100, Donald C. Vinh108, Horst von Bernuth109, Joost Wauters110, Carine Wouters100, Aysun Yahsi42, Saliha Kanik Yuksek42, Mayana Zatz111, Pawel Zawadzki112, Helen C. Su71, Jean-Laurent Casanova113

1. Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France; University of Paris, Imagine Institute, Paris, France
2. Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden; Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
3. San Raffaele Telethon Institute for Gene Therapy, IRCCS Ospedale San Raffaele, and Vita Salute San Raffaele University, Milan, Italy
4. Necmettin Erbakan University, Konya, Turkey
5. Immunology Research Lab, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia
6. Dasman Diabetes Institute, Department of Genetics and Bioinformatics, Dasman, Kuwait
7. Selcuk University, Konya, Turkey
8. Diabetes Center, University of California San Francisco, San Francisco, CA
9. Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
10. St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY; Primary Immunodeficiencies Group, Department of Microbiology and Parasitology, School of Medicine, University of Antioquia, Medellín, Colombia; School of Microbiology, University of Antioquia UdeA, Medellín, Colombia

11. Immunology Laboratory, Averroes University Hospital and Laboratory of Clinical Immunology Inflammation and Allergy, Faculty of Medicine and Pharmacy, Hassan 2 University, Casablanca, Morocco

12. The Genetics Institute, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

13. Pediatric Nephrology, Rheumatology, Dermatology, HFME, Hospices Civils de Lyon, National Referee Centre RAISE, and INSERM U1111, Université de Lyon, Lyon, France.

14. Department of Pediatrics, BC Children’s and St. Paul’s Hospitals, University of British Columbia, Vancouver, BC, Canada

15. Icahn School of Medicine at Mount Sinai, New York, NY

16. Helix, San Mateo, CA

17. Shupyk National Medical Academy for Postgraduate Education, Kiev, Ukraine

18. Clinical Immunology Unit, Department of Pediatric Infectious Disease, CHU Ibn Rushd and LICIA, Laboratoire d’Immunologie Clinique, Inflammation et Allergie, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco

19. Bursa City Hospital, Bursa, Turkey

20. SciLifeLab, Department Of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
21. Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden
22. Stanford University, Stanford, CA
23. Division of Immunology, Allergy, and Rheumatology, Department of Pediatrics and the Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA
24. Clinical Genomics, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy
25. Murdoch Children’s Research Institute and Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
26. Immunology Division, Genetics Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute, Vall d’Hebron, Barcelona Hospital Campus, UAB, Barcelona, Catalonia, Spain
27. Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
28. de Duve Institute and Ludwig Cancer Research, Brussels, Belgium
29. Washington University School of Medicine, St. Louis, MO
30. The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD; Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD
31. Bai Jerbai Wadia Hospital for Children, Mumbai, India
32. School of Medicine and Public Health, University of Wisconsin, Madison, WI
33. Genetics Unit, Military Hospital Mohamed V, Rabat, Morocco
34. Ondokuz Mayis University, Samsun, Turkey

35. Instituto Nacional de Pediatría (National Institute of Pediatrics), Mexico City, Mexico

36. School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

37. Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid; Genomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain

38. Group of Primary Immunodeficiencies, University of Antioquia UDEA, Medellin, Colombia.

39. Pulmonology Department, Cliniques Universitaires Saint-Luc; Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium

40. Feinstein Institute for Medical Research, Northwell Health USA, Manhasset, NY

41. Center for Chronic Immunodeficiency & Institute for Immunodeficiency, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

42. Ankara City Hospital, Ankara, Turkey

43. Department of Paediatric Immunology and Pulmonology, Centre for Primary Immunodeficiency Ghent (CPIG), PID Research Laboratory, Jeffrey Modell Diagnosis and Research Centre, Ghent University Hospital, Ghent, Belgium

44. The Genetics Institute Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

45. Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates

46. Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden

47. Institute for Systems Biology, Seattle, WA
48. Department of Pediatrics, Division of Allergy Immunology, Children’s Hospital of Philadelphia, Philadelphia, PA; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
49. Departments of Pediatrics, Immunology and Microbiology, University of Colorado, School of Medicine, Aurora, CO
50. Department of Medicine, Haukeland University Hospital, Bergen, Norway
51. Department of Community Pediatrics, Perinatal and Maternal Medicine, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
52. Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
53. Department of Pediatrics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
54. Laboratory of Neurogenetics of Language and Howard Hughes Medical Institute, The Rockefeller University, New York, NY
55. Bioinformatics and Applied Genomics Unit, Hellenic Pasteur Institute, Athens, Greece
56. Prof.Dr.Cemil Taşçıoğlu City Hospital, Istanbul, Turkey
57. Molecular Pathology, Department of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
58. Chang Gung University, Taoyuan County, Taiwan
59. Department of Paediatrics & Adolescent Medicine, The University of Hong Kong, Hong Kong, China
60. Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
61. Department of Immunobiology, Yale University School of Medicine, New Haven, CT
62. Zukerman Mind Brain Behavior Institute, Columbia University, New York, NY
63. Department of Clinical Immunology and Infectious Diseases, National Research Institute of Tuberculosis and Lung Diseases, The Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Masih Daneshvari Hospital, Shahid Beheshti, University of Medical Sciences, Tehran, Iran
64. Primary Immunodeficiency Clinical Unit and Laboratory, Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
65. Department of Pediatrics, University Hospitals Leuven; KU Leuven, Department of Microbiology, Immunology and Transplantation; Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium
66. Department of Pediatrics, Columbia University Irving Medical Center, New York, NY
67. University Clinic for Children’s Diseases, Department of Pediatric Immunology, Medical Faculty, University “St.Cyril and Methodij” Skopje, North Macedonia
68. Department of Biomedicine, Aarhus University, Aarhus, Denmark
69. Tokyo Medical & Dental University Hospital, Tokyo, Japan
70. A*STAR Infectious Disease Labs, Agency for Science, Technology and Research, Singapore; Lee Kong Chian School of Medicine, Nanyang Technology University, Singapore
71. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
72. Laboratory of Medical Genetics, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy
73. Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy
74. Comparative Immunology Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland
75. Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
76. Tokyo Medical and Dental University, Tokyo, Japan
77. Department of Molecular Biology and Genetics, Bilkent University, Bilkent - Ankara, Turkey
78. Haitian Study Group for Kaposi’s Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti
79. Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey
80. Institute of Biomedical Research of IdiPAZ, University Hospital “La Paz”, Madrid, Spain.
81. Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ
82. Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari A. Moro, Bari, Italy
83. IIBB-CSIC, IDIBAPS, Barcelona, Spain
84. Central European Institute of Technology, Masaryk University, Brno, Czech Republic
85. Faculdades Pequeno Príncipe, Instituto de Pesquisa Pelê Pequeno Príncipe, Curitiba, Brazil
86. Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain; Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain; Center for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain
87. Human Evolutionary Genetics Unit, CNRS U2000, Institut Pasteur, Paris, France; Human Genomics and Evolution, Collège de France, Paris, France
88. Al Jalila Children’s Hospital, Dubai, United Arab Emirates
89. University Hospital St. Marina, Varna, Bulgaria

90. Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

91. Department of Immunology, University Hospital of Gran Canaria Dr. Negrin, Canarian Health System, Las Palmas de Gran Canaria; Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain

92. Department of Paediatric Infectious Diseases and Virology, Imperial College London, London, UK; Centre for Paediatrics and Child Health, Faculty of Medicine, Imperial College London, London, UK

93. Department of Immunology, Second Faculty of Medicine Charles University, V Uvalu, University Hospital in Motol, Prague, Czech Republic

94. Adult Immunodeficiency Unit, Infectious Diseases, Inflammation Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Rare Diseases Center and Pediatric Research Center, Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

95. Specialized Immunology Laboratory of Dr. Shahrooei, Ahvaz, Iran; Department of Microbiology and Immunology, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium

96. Department of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

97. Central European Institute of Technology & Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
98. Department of Pharmacology & Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD

99. Pediatric Infectious Diseases and Immunodeficiencies Unit, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain

100. Department of Pediatrics University Hospitals Leuven, Leuven, Belgium

101. St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands

102. Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria

103. Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia; St Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia

104. BC Children’s Hospital, The University of British Columbia, Vancouver, Canada

105. Centre for Precision Therapeutics, Genetics & Genomic Medicine Centre, NeuroGen Children’s Healthcare and Lecturer, Holy Family Red Crescent Medical College Dhaka, Bangladesh

106. College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, UAE; Cellular Intelligence (Ci) Lab, GenomeArc Inc., Toronto, Ontario, Canada

107. Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands

108. Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, Montréal, Québec, Canada; Infectious Disease Susceptibility Program, Research Institute, McGill University Health Centre, Montréal, Québec, Canada
109. Department of Pediatric Pneumology, Immunology and Intensive Care, Charité Universitätsmedizin, Berlin University Hospital Center, Berlin, Germany; Labor Berlin GmbH, Department of Immunology, Berlin, Germany; Berlin Institutes of Health (BIH), Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany

110. Department of General Internal Medicine, Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium

111. Biosciences Institute, University of São Paulo, São Paulo, Brazil

112. Molecular Biophysics Division, Faculty of Physics, A. Mickiewicz University, Poznań, Poland

113. The Rockefeller University & Howard Hughes Medical Institute, New York, NY; Necker Hospital for Sick Children & INSERM, Paris, France